Proactive Investors - Run By Investors For Investors

Shire shares in demand after Liberum turns positive on FTSE 100 druggie

The ‘buy’ call was made on valuation grounds with the stock having fallen 21% since the start of June
Shire shares in demand after Liberum turns positive on FTSE 100 druggie
Shire investors had a skip in their step

Shares in the FTSE 100 druggie Shire PLC (LON:SHP) were in demand late morning following an upgrade by the City broker Liberum.

The ‘buy’ call was made on valuation grounds with the stock having fallen 21% since the start of June.

READ: Shire shares nudge higher at midday after third quarter results beat

Liberum says the risk of a new Shire competitor in the haemophilia market has now been baked into the company’s valuation as has the prospect of management making further big and potentially tricky acquisitions.

Risks now discounted

“With the stock now below £35, we believe almost the entire value of hemophilia has been discounted from the shares,” Liberum said in a note to clients.

“Furthermore, there are welcome signs that management could re-orient from away from M&A to cash returns as it looks at strategic options for neuroscience.”

It has moved its recommendation to ‘buy’ from ‘hold’, while its price target is £42 a share.

In the afternoon session, stock in Shire had nudged up to 3,573p, a rise of 74p (and mainly the result of the Liberum note).

Of the 17 analysts logged as following Shire by the Broker Forecasts site, 15 hold ‘buy’ recommendations. The remainder see the equity as fully valued. The consensus price target is £49.37.

View full SHP profile View Profile

Shire Plc Timeline

Related Articles

consumer health segment overview
September 16 2018
The company sells clinically validated anti-ageing products for hair, skin and body.
eye
November 19 2018
“It’s a blended model of highly cash generative assets and top line growth”
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use